About The Webinar...
Treatment for hepatitis C in Australia is set to change with new medicines to become available soon. To find out what this means for you please attend the New Hepatitis C Treatment – What you need to know webcast.
Presenters: Professor Greg Dore and Kevin Marriott
Policy Officer, Hepatitis Australia
Kevin has been working in the blood borne viruses, community sector for 20 years. He has previously worked in Tasmania and Queensland and is currently the Policy Officer with Hepatitis Australia. Kevin has recently been responsible for national submissions to the Australia Government including the Pharmaceutical Benefits Advisory Committee, Therapeutic Goods Authority and the Parliamentary Inquiry into Hepatitis C in Australia.
Professor Greg Dore
Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Australia, and Infectious Diseases Physician, St Vincent’s Hospital, Sydney, Australia
Professor Dore is Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Australia, and Infectious Diseases Physician, St Vincent’s Hospital, Sydney, Australia. He has been involved in viral hepatitis and HIV epidemiological and clinical research, clinical care and public health policy for 20 years. He has been involved in many hepatitis C clinical trials, including with interferon-free direct acting regimens, and is an international leader in evaluation of these regimens among people who inject drugs.
He has published over 250 peer-reviewed publications and is editor of two books on hepatitis C. Professor Dore’s leadership in clinical practice and research is demonstrated through his recent Presidency of the Australasian Society for HIV Medicine (ASHM), current membership of NHMRC Council, and position as a NHMRC Practitioner Fellow.